PMID- 17950805
OWN - NLM
STAT- MEDLINE
DCOM- 20071220
LR  - 20131121
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 100
IP  - 9
DP  - 2007 Nov 1
TI  - Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular 
      heart disease.
PG  - 1442-5
AB  - Valvular heart disease, inducing valvular regurgitation, has been described in 
      users of drugs such as anorectic agents and ergot derivates. 
      3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") also leads in vitro to the 
      proliferation of cardiac valvular interstitial cells by activation of the 
      5-hydroxytryptamine 2B receptor. The aim of this study was to determine the 
      occurrence of valvulopathy in young adults taking MDMA. Twenty-nine subjects 
      using or having used MDMA and 29 gender- and age-matched controls were blindly 
      evaluated with echocardiography. Eight subjects (28%) who took MDMA had abnormal 
      echocardiographic results using the United States Food and Drug Administration's 
      criteria for appetite suppressant-induced valvular heart disease, compared with 
      none in the control group (p = 0.0045). Six (21%) subjects had mitral 
      regurgitation of 1/4 and 4 (14%) of > or =2/4, compared with none in the control 
      group (p = 0.002). The mean mitral regurgitant area ratios (jet/atrium) were 12 
      +/- 9.8% and 5 +/- 1.3%, respectively (p = 0.007). Tricuspid regurgitation > or 
      =2/4 was present in 13 MDMA users (45%) and absent in controls (p <0.001). The 
      mean tricuspid regurgitant area ratios were 19 +/- 9.5% and 9 +/- 4.5%, 
      respectively (p <0.001). Four MDMA users (14%) had mild aortic regurgitation (p = 
      0.11). Valvular "strands" were present in 6 MDMA users (21%) and in none of the 
      controls (p = 0.02). In conclusion, MDMA may lead to mild to moderate valvular 
      heart disease and valvular strands.
FAU - Droogmans, Steven
AU  - Droogmans S
AD  - Department of Cardiology, Universitair Ziekenhuis Brussel, Brussels, Belgium. 
      steven_droogmans@yahoo.com
FAU - Cosyns, Bernard
AU  - Cosyns B
FAU - D'haenen, Hugo
AU  - D'haenen H
FAU - Creeten, Edwin
AU  - Creeten E
FAU - Weytjens, Caroline
AU  - Weytjens C
FAU - Franken, Philippe R
AU  - Franken PR
FAU - Scott, Benjamin
AU  - Scott B
FAU - Schoors, Danny
AU  - Schoors D
FAU - Kemdem, Arsene
AU  - Kemdem A
FAU - Close, Laurent
AU  - Close L
FAU - Vandenbossche, Jean-Luc
AU  - Vandenbossche JL
FAU - Bechet, Serge
AU  - Bechet S
FAU - Van Camp, Guy
AU  - Van Camp G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070828
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Hallucinogens/*adverse effects
MH  - Heart Valve Diseases/*chemically induced
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects
MH  - Substance-Related Disorders/*complications
EDAT- 2007/10/24 09:00
MHDA- 2007/12/21 09:00
CRDT- 2007/10/24 09:00
PHST- 2007/04/27 00:00 [received]
PHST- 2007/06/10 00:00 [revised]
PHST- 2007/06/10 00:00 [accepted]
PHST- 2007/10/24 09:00 [pubmed]
PHST- 2007/12/21 09:00 [medline]
PHST- 2007/10/24 09:00 [entrez]
AID - S0002-9149(07)01463-4 [pii]
AID - 10.1016/j.amjcard.2007.06.045 [doi]
PST - ppublish
SO  - Am J Cardiol. 2007 Nov 1;100(9):1442-5. doi: 10.1016/j.amjcard.2007.06.045. Epub 
      2007 Aug 28.